[

glenmark

]
Glenmark Life Sciences is a leading developer and manufacturer of select high-value, non-commoditised active pharmaceutical ingredients in chronic therapeutic areas.(Representative Photo/Reuters)

Glenmark Life Sciences IPO share allotment today, listing expected on Aug 6

By hindustantimes.com | Edited by Amit Chaturvedi, Hindustan Times, New Delhi
PUBLISHED ON AUG 03, 2021 10:56 AM IST
Glenmark Life Sciences IPO opened for three days last month and was subscribed nearly 45 times. Its price range was at 695-720 per share and the lot size was 20. Ahead of its IPO, Glenmark Life Sciences raised 454 crore from anchor investors.
Glenmark Life Sciences IPO will open for three days. (Representative Photo)
Glenmark Life Sciences IPO will open for three days. (Representative Photo)

Glenmark Life Sciences IPO to open tomorrow. Check details

By hindustantimes.com | Written by Meenakshi Ray, New Delhi
PUBLISHED ON JUL 26, 2021 10:49 AM IST
Glenmark Life Sciences IPO will have a fresh issue of equity shares worth up to 1,060 crore and an offer for sale (OFS) of up to 63 lakh equity shares by Glenmark Pharmaceuticals.
The FAITH study enrolled a total of 158 hospitalised patients with moderate symptoms of Covid-19 in India.(REUTERS File)
The FAITH study enrolled a total of 158 hospitalised patients with moderate symptoms of Covid-19 in India.(REUTERS File)

Combination of antiviral drugs shows ‘no superior outcome’ for Covid treatment: Firm

Hindustan Times, New Delhi | By Rhythma Kaul
PUBLISHED ON OCT 10, 2020 10:04 AM IST
In May, Glenmark had received approval from DCGI to conduct phase 3 clinical trials in the country using a combination of antiviral drugs Favipiravir and Umifenovir as a potential Covid-19 treatment strategy
Mumbai-based Glenmark in July said its version of favipiravir alone showed promise in a late-stage study of patients with mild to moderate coronavirus infection.(ANI)
Mumbai-based Glenmark in July said its version of favipiravir alone showed promise in a late-stage study of patients with mild to moderate coronavirus infection.(ANI)

Glenmark’s antiviral combination for moderate Covid-19 shows no clinical benefit

Bengaluru | By Reuters| Posted by Susmita Pakrasi
UPDATED ON OCT 09, 2020 08:44 PM IST
Favipiravir is made under the brand name Avigan by Japan’s Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014, while umifenovir is licensed as a treatment for some types of flu infections in Russia and China.
The antiviral oral drug is marketed under the brand name FabiFlu and was formally launched in the country on June 21.(Reuters)
The antiviral oral drug is marketed under the brand name FabiFlu and was formally launched in the country on June 21.(Reuters)

Glenmark Pharma drops price of Covid-19 drug Favipiravir to Rs 75/tablet

Hindustan Times, New Delhi | By Rhythma Kaul
UPDATED ON JUL 13, 2020 09:28 PM IST
The Drugs Controller General of India (DCGI) granted it approval for Covid-19 treatment under emergency use authorisation, which means since there is limited data available on the medicine’s performance on Covid-19 positive cases, doctors prescribing it would have to document the written consent of a patient.
The medicine can be administered to coronavirus patients between the age group of 18 and 75.(BLOOMBERG PHOTO.)
The medicine can be administered to coronavirus patients between the age group of 18 and 75.(BLOOMBERG PHOTO.)

Glenmark’s FabiFlu gets DCGI nod as Covid-19 drug, in stores next week: All you need to know

Hindustan Times, New Delhi | By hindustantimes.com | Edited by Sohini Sarkar
UPDATED ON JUN 20, 2020 10:44 PM IST
Bringing some relief for Covid-19 patients, even as the country reported an all-time high of 14,516 new coronavirus cases on Saturday, the drug will soon be available in hospitals and stores in a pack of 34 oral tables at moderately affordable prices.
Shares of Glenmark Pharmaceuticals closed at Rs 409.10 per scrip on the BSE, up 0.93 per cent from its previous close.(AP)
Shares of Glenmark Pharmaceuticals closed at Rs 409.10 per scrip on the BSE, up 0.93 per cent from its previous close.(AP)

Glenmark gets India approval for favipiravir as Covid-19 treatment

Bengaluru | By Press Trust of India
PUBLISHED ON JUN 19, 2020 08:25 PM IST
The company has received the manufacturing and marketing approval from Drugs Controller General of India (DCGI) to launch favipiravir for the treatment of mild to moderate COVID-19 patients, it said.
Finished tablets sit inside an unsealed container during the manufacture of the Favipiravir antiviral medicine at a plant in Khimki, Russia.(Bloomberg)
Finished tablets sit inside an unsealed container during the manufacture of the Favipiravir antiviral medicine at a plant in Khimki, Russia.(Bloomberg)

Glenmark to study efficacy of two antiviral drugs for treating Covid-19

Hindustan Times, New Delhi | By Rhythma Kaul
UPDATED ON MAY 26, 2020 05:36 PM IST
Favipiravir is an oral antiviral drug approved in Japan since 2014 for treating novel or re-emerging influenza virus infections. Umifenovir is another oral antiviral drug licenced for the treatment and prophylaxis of influenza A and B infections in Russia and China.
Glenmark Pharmaceuticals has initiated phase three of clinical trials in India on antiviral tablet Favipiravir, becoming the first company in the country to do so in Mumbai on Tuesday.(ANI File Photo)
Glenmark Pharmaceuticals has initiated phase three of clinical trials in India on antiviral tablet Favipiravir, becoming the first company in the country to do so in Mumbai on Tuesday.(ANI File Photo)

Glenmark to start new phase 3 clinical trial of Covid-19 drug combination

Mumbai | By Asian News International | Posted by Kanishka Sarkar
UPDATED ON MAY 26, 2020 11:50 AM IST
A total of 158 hospitalised patients of moderate Covid-19 infection will be enrolled in the combination study and randomised in two groups.
Glenmark Pharmaceuticals has initiated phase three of clinical trials in India on antiviral tablet Favipiravir, becoming the first company in the country to do so, in Mumbai on Tuesday.(ANI)
Glenmark Pharmaceuticals has initiated phase three of clinical trials in India on antiviral tablet Favipiravir, becoming the first company in the country to do so, in Mumbai on Tuesday.(ANI)

Glenmark begins phase 3 clinical trials of favipiravir

Hindustan Times, New Delhi | By Rhythma Kaul
UPDATED ON MAY 13, 2020 04:58 AM IST
Glenmark Pharmaceuticals Limited will be looking at recruiting patients from hospitals in the red zones of states such as Gujarat, Maharashtra and Delhi where the Covid-19 case load is high.
The DCGI approved to conduct trials on Favipiravir antiviral tablets on Covid-19 patients, making Glenmark the first pharmaceutical firm in India to be given an approval to start the trial.(AFP)
The DCGI approved to conduct trials on Favipiravir antiviral tablets on Covid-19 patients, making Glenmark the first pharmaceutical firm in India to be given an approval to start the trial.(AFP)

Glenmark gets DGCI nod for clinical trial

Hindustan Times, New Delhi | By Rhythma Kaul
PUBLISHED ON MAY 01, 2020 03:49 AM IST
Favipiravir, sold under the brand name Avigan of Fujifilm Toyama Chemical Co. Ltd, Japan, a subsidiary of Fujifilm Corporation, is an antiviral medication used to treat influenza in Japan.
The hospital had allegedly conducted the trial on 17 people from Churu district.(Getty Images/iStockphoto/Representative image)
The hospital had allegedly conducted the trial on 17 people from Churu district.(Getty Images/iStockphoto/Representative image)

Pharma company suspends clinical trial at Jaipur hospital

Hindustan Times, Jaipur | By HT Correspondent, Jaipur
UPDATED ON APR 24, 2018 10:34 PM IST
Drug controller-II, Jaipur, has said that a second DCGI team will probe the matter further.
SHARE
Story Saved